Sensei Biotherapeutics (NASDAQ:FTH) Research Coverage Started at TD Cowen

by · The Markets Daily

TD Cowen assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH – Free Report) in a report published on Wednesday, MarketBeat.com reports. The firm issued a buy rating on the stock.

FTH has been the topic of a number of other research reports. Citigroup assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target on the stock. BTIG Research reiterated a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Wall Street Zen upgraded shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Read Our Latest Research Report on Sensei Biotherapeutics

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ FTH opened at $37.44 on Wednesday. The firm’s 50-day moving average is $31.34. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14. The firm has a market cap of $967.45 million, a price-to-earnings ratio of -0.26 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, analysts predict that Sensei Biotherapeutics will post -13.18 earnings per share for the current year.

Insider Activity at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CEO Anand Kiran Parikh purchased 2,806 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the acquisition, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brian C. Stephenson acquired 9,391 shares of Sensei Biotherapeutics stock in a transaction dated Wednesday, June 24th. The stock was acquired at an average cost of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at $700,388.52. This trade represents a 53.93% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 49,494 shares of company stock worth $1,188,822. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Large investors have recently bought and sold shares of the stock. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Bank of America Corp DE raised its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the last quarter. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

Read More